References
- Clozapine Study Group. The safety and efficacy of clozapine in severe treatment -resistant schizophrenic patients in the UK. British Journal of Psychiatry 1993; 163: 150–154.
- Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment resistant schizophrenic. A double blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789–796.
- Meltzer HY. Dimensions of outcome with clozapine. British Journal of Psychiatry 1992; 160 (suppl. 17) 46–53.
- King DJ and Mills PJ. Clozapine: the holywell experience with the first 24 patients. Irish Journal of Psychological Medicine, Feb 1993; 10(1): 30–34.
- McKenna PJ, Bailey PE. The strange story of clozapine. British Journal of Psychiatry 1993; 162: 32 – 37.
- Meltzer H, Cola P, Way L et al. Cost effectiveness of clozapine in antipsychotic-resistant schizophrenia. American Journal of Psychiatry 1993; 150: 11.
- Revicki DA, Luce BR, Weschler JM et al. Cost effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry 1990; 41(8): 850–854.
- Chui E, Burrows G, Stevenson J. Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Australian and New Zealand Journal of Psychiatry 1976; 10: 343–347.
- Borison RL, Diamond BI, Sinha D et al. Clozapine withdrawal rebound psychosis. Psychopharmacology Bulletin 1988; 24: 260–263.
- Claghorn J, Honigfeld G, Abuzzahab FS et al. The risks and benefits of clozapine versus chlorpromazine. Journal of Clinical Psychopharmacology 1987; 7: 377–84.
- Conley RR, Schulz SC, Baker RW et al. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacology Bulletin 1988; 24: 269–74.
- Herrera JM, Costa J, Sramek J et al. Clozapine in refractory schizophrenia. Schizophrenia Research 1988; 1: 305–6.
- Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hospital and Community Psychiatry 1994; 45: 261–264.
- Shepherd M, Watt D, Falloon IRH et al. The natural history of schizophrenia: a five year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine Monograph Supplement 1989; 15: 1–46.
- Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment resistant schizophrenia in the united kingdom. British Journal of Psychiatry 1993; 162: 38–42.